Itolizumab
- Generic Name
- Itolizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1116433-11-4
- Unique Ingredient Identifier
- XQQ2RHV14N
- Background
Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
- Associated Conditions
- -
- Associated Therapies
- -
Investors Hammer Lilly as GLP-1 Sales Miss Forecasts
Eli Lilly's Q3 sales of GLP-1 drugs Mounjaro and Zepbound missed analyst projections, leading to a stock decline and lowered revenue guidance for 2024. Despite strong underlying growth, factors like inventory cuts and 'lumpiness' in stocking contributed to the shortfall. Lilly plans to boost marketing efforts for the drugs.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath